Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STABLED: Catheter Ablation plus Edoxaban vs Standard Medical Therapy in Post-Stroke Non-valvular Atrial Fibrillation
jRCTs031180249Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of edoxaban in nonvalvular atrial fibrillation (NVAF), ischemic stroke, systemic embolism and 1 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary composite endpoint. Started Mar 2018; status: completed.
02
Drugs
edoxaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)ischemic strokesystemic embolismheart failure (HF)
Beyond the preview
Go deeper on jRCTs031180249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180249.